Supernus Pharma (SUPN) Cited for Making False or Misleading Claims About Risks Associated with Oxtellar XR
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Supernus Pharma (NASDAQ: SUPN) received a letter from the FDA for making false or misleading claims about risks associated with Oxtellar XR.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Acacia Communications (ACIA) Mentioned as Short in Lakewood Capital's Q3 Letter - Bloomberg
- American Express (AXP) Elects John Brennan to Board of Directors
- Amicus Therapeutics (FOLD) Announces Presentations, Posters at WORLDSymposium
Create E-mail Alert Related CategoriesCorporate News, FDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!